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Abstract
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about
ibrutinib’s effects on other electrocardiographic parameters, particularly the QT interval. Using our database of 137 patients
treated with ibrutinib, we retrospectively identified 21 patients in whom an electrocardiogram (ECG) was obtained both prior to
and after ibrutinib exposure. All traditional ECG parameters as well as QT dispersion were manually measured by an electrophysiologist. Compared to baseline ECGs, post ibrutinib ECGs demonstrated QT interval shortening from 386 ms to 356 ms (P ¼
.007), corrected QT interval shortening using Bazett’s formula from 446 ms to 437 ms (P ¼ .04), and corrected QT interval
shortening using Fridericia’s formula from 425 ms to 407 ms (P ¼ .003). QT dispersion also increased post ibrutinib exposure
compared to baseline (39.8 ms vs 57.3 ms, P ¼ .002). There was no significant change in other ECG parameters. In conclusion,
both the absolute and corrected QT intervals significantly shortened after ibrutinib exposure, while there was a significant
increase in QT dispersion. These findings may point to a common underlying electrophysiologic mechanism of ibrutinibassociated arrhythmias.
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Ibrutinib is a small molecular inhibitor of Bruton tyrosine
kinase (BTK) used to treat multiple B-cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma.
Despite its anticancer efficacy, multiple cardiotoxicities have
been identified including both atrial and ventricular arrhythmias.1-3 Prior studies have shown that ibrutinib is an independent risk factor for the development of atrial arrhythmias with
rates of atrial fibrillation in excess of 10% to 15%.4-6 Aside
from the development of frank arrhythmias, little is known
about the potential effects of ibrutinib on electrocardiographic
(ECG) parameters. Although significant QT prolongation was
not identified during clinical trials, other ECG parameters have
not been systematically evaluated. We hypothesized that ibrutinib will influence easily measured ECG parameters that may
help direct future basic and translational research into its
arrhythmic effects.
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Table 1. Baseline Patient Demographics.a
Age, mean years (SD)

64 (9.1)

Male sex
16 (76%)
29.5 (5.9)
BMI: mean (kg/m2 [SD])
Ever smokers
15 (71%)
Baseline cardiovascular disease
Coronary artery disease
5 (24%)
Valvular disease
4 (19%)
Hypertension
12 (57%)
Diabetes
5 (24%)
Hyperlipidemia
9 (43%)
Cardiomyopathy
0 (0%)
Stroke
0 (0%)
Baseline cardiovascular medications
Angiotensin converting enzyme inhibitors/angiotensin
6 (29%)
II receptor blockers
Beta blockers
7 (33%)
Nondihydropyridine calcium channel blockers
1 (5%)
Digoxin
1 (5%)
Statin
4 (19%)
Aspirin
7 (33%)
Antiarrhythmics
0 (0%)
Malignancy
Chronic lymphocytic leukemia
12 (57%)
Mantle cell lymphoma
9 (43%)
Waldenstrom macroglobulinemia
0
Ibrutinib dose, mg, mean (SD)
440 (117)
Abbreviation: BMI, body mass index.
a
N ¼ 21.

Details of this study population have been previously
described.4 In brief, patients diagnosed with B-cell malignancies were derived from the Moffitt Cancer Center (MCC)
Malignant Hematology Program and those who completed at
least one 28-day cycle of ibrutinib between January 1, 2010,
and December 31, 2017, were selected. In this analysis, only
patients with an ECG completed prior to and during ibrutinib
therapy were included. Baseline demographics and cardiovascular risk factors were abstracted from medical records, and
ECG parameters including rate, rhythm, QRS axis, PR interval,
QRS duration, QT interval, Bazett and Fridericia corrected QT
interval, and QT dispersion (QT maximum  QT minimum)
were manually calculated by the study electrophysiologist
(M.G.F.). Given that there was no discrepancy of >20 ms
between the automated and manual measurements, only 1 electrophysiologist adjudicated the results. Electrocardiographs
were performed on General Electric (GE) Mac 5500 machines
with standard recording algorithms including paper speed
(25 mm/s) and scale (10 mm/mV). Descriptive statistics was
used to characterize the baseline demographics and Student
t test were used to test for statistically significant changes in
the ECG variables.
Characteristics of the entire study population are previously
published including a 13.7% incidence of atrial arrhythmias.4
From the original study population, 21 patients met the inclusion criteria for the current analysis. Baseline characteristics
of these patients are presented in Table 1. The mean age was

Table 2. Changes in ECG Parameters Associated With Ibrutinib
Exposure.
ECG changes
Rate (beats per minute)
PR interval (ms)
QRS duration (ms)
QRS axis (degrees)
QT interval (ms)
QTc Bazett (ms)
QTc Fridericia (ms)
QT dispersion (ms)

Before
ibrutinib (SD)

After
ibrutinib (SD)

P valuea

82 (14)
157 (14)
101 (15)
2.3 (37)
386 (26)
446 (33)
425 (24)
38.8 (18)

94 (25)
151 (24)
106 (22)
8.1 (41)
356 (39)
437 (30)
407 (26)
55.7 (24)

.06
.60
.12
.14
.007
.04
.003
.005

Abbreviation: ECG, electrocardiography.
a
Bold values are statistically significant.

64 years and 76% were male. The majority of patients were
treated for chronic lymphocytic leukemia (57%). The median
time from baseline ECG to ibrutinib initiation was 352 days,
and median time from drug initiation to follow-up ECG acquisition was 105 days. All patients in this analysis completed
more than 1 cycle of ibrutinib therapy. Compared to pretreatment baseline ECGs, postibrutinib ECGs demonstrated QT
interval shortening from 386 ms to 356 ms (P ¼ .007) corrected
QT interval shortening using Bazett formula from 446 ms to
437 ms (P ¼ .04) and using the Fridericia formula from 425 ms
to 407 ms (P ¼ .003). QT dispersion also increased postibrutinib exposure compared to baseline (39.8 ms vs 57.3 ms, P ¼
.002). There were no significant changes for other common
ECG parameters (Table 2). Of note, ECG parameters were
normally distributed based on the Shapiro-Wilk test for
normality.
This is the largest study to systematically evaluate ECG
changes in the setting of ibrutinib use. The main finding was a
significant shortening of the QT interval with an increase in
QT dispersion. de Jong and colleagues published data from a
prospective “thorough QT study,” demonstrating a nonsignificant shortening of the QT interval.7 Nevertheless, fewer
patients were evaluated and only received 1 dose of ibrutinib
with the final ECG checked 72 hours after administration. In
our “real-world” sample, patients received daily ibrutinib use,
and the median time to ECG evaluation was 105 days, which
likely explains the statistical significance reported in our
study. QT interval changes can be associated with both shortand long-term potential cardiovascular complications
including atrial and ventricular arrhythmias as well as sudden
cardiac death.
Multiple studies have reported that ibrutinib use is associated with increased rates of both atrial and ventricular arrhythmias; however, the underlying mechanism of this drug’s
arrhythmogenicity remains unclear. Although ibrutinib has
been shown to impact the PI3K-AKT signaling pathway, which
has been implicated in the development of AF,8 this may not be
sufficient to explain the mechanism of ibrutinib-induced AF.
Calcium ions play a significant role in the electrophysiology of
both atrial and ventricular myocytes and may help to explain
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ibrutinib’s arrhythmogenesis. Using a murine model, Jiang and
colleagues identified potential mechanisms for ibrutinibassociated AF including dysregulated calcium handling,
enhanced delayed afterdepolarization, and increased activity
of CaMKII.9 In a rabbit model of long QT syndrome, the
administration of an inhibitor of sarcoplasmic reticulum calcium cycling led to prolongation of the action potential duration (APD) with enhancement of the calcium transient
amplitude.10 Interestingly, this is the opposite effect seen in
atrial myocytes when exposed to ibrutinib. Extrapolating on
this finding, a similar effect may occur with ventricular myocytes that would translate to QT interval shortening. It should
be recognized that both the QT interval and QT dispersion have
significant limitations in predicting arrhythmic events
however.11
We recognize several limitations with this analysis. First,
this was a retrospective study at a single cancer center with the
associated inherent biases. We acknowledge the sample size is
a small percentage of our original cohort which could introduce
selection bias; however, baseline ECGs are not routinely
obtained in this patient population. There are no recommendations for ECG monitoring in patients treated with ibrutinib, and
therefore, we had to rely on those ECGs obtained for other
clinical reasons. As such, the lack of standard intervals for
baseline and follow-up ECGs in this study can lead to the
introduction of significant bias. It is also recognized that the
QT interval varies with activity and the circadian cycle; however, all ECGs were obtained during waking hours, and the use
of standardized heart rate correction formulae should minimize
these potential biases. Finally, we cannot comment on the association of these ECG abnormalities and the development of
arrhythmias as ECGs were commonly checked in individuals
with signs or symptoms of abnormal heart rhythms.
In summary, our study is the first to report ECG changes
associated with ibrutinib exposure. Ibrutinib leads to significant QT/QTc shortening and an increase in QT dispersion.
These findings provide a foundation for the development of
future basic and translational studies to identify the mechanism
of ibrutinib-induced arrhythmogenesis.
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